vs
Side-by-side financial comparison of Ladder Capital Corp (LADR) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $13.7M, roughly 1.6× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 71.0%, a 4.7% gap on every dollar of revenue. Ladder Capital Corp produced more free cash flow last quarter ($78.7M vs $-2.1M).
Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
LADR vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.3M | $13.7M |
| Net Profit | $15.9M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 69.5% | -86.5% |
| Net Margin | 71.0% | 75.7% |
| Revenue YoY | -18.0% | — |
| Net Profit YoY | -49.4% | 179.1% |
| EPS (diluted) | $0.13 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.3M | $13.7M | ||
| Q3 25 | $27.8M | $19.1M | ||
| Q2 25 | $21.5M | $8.1M | ||
| Q1 25 | $20.3M | $2.9M | ||
| Q4 24 | $27.2M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $34.3M | — | ||
| Q1 24 | $37.1M | — |
| Q4 25 | $15.9M | $10.4M | ||
| Q3 25 | $19.2M | $-16.3M | ||
| Q2 25 | $17.1M | $-15.8M | ||
| Q1 25 | $11.6M | $-13.3M | ||
| Q4 24 | $31.3M | — | ||
| Q3 24 | $27.6M | — | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $16.4M | — |
| Q4 25 | 69.5% | -86.5% | ||
| Q3 25 | 72.4% | -10.1% | ||
| Q2 25 | 96.7% | -177.7% | ||
| Q1 25 | 52.7% | -472.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 90.4% | — | ||
| Q1 24 | 49.4% | — |
| Q4 25 | 71.0% | 75.7% | ||
| Q3 25 | 69.0% | -85.4% | ||
| Q2 25 | 79.5% | -196.0% | ||
| Q1 25 | 56.8% | -452.7% | ||
| Q4 24 | 115.1% | — | ||
| Q3 24 | 71.7% | — | ||
| Q2 24 | 93.6% | — | ||
| Q1 24 | 44.2% | — |
| Q4 25 | $0.13 | $-3.74 | ||
| Q3 25 | $0.15 | $-0.11 | ||
| Q2 25 | $0.14 | $-0.16 | ||
| Q1 25 | $0.09 | $-0.18 | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $0.22 | — | ||
| Q2 24 | $0.26 | — | ||
| Q1 24 | $0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.0M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $35.3M |
| Total Assets | $5.2B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.0M | $137.5M | ||
| Q3 25 | $49.4M | $103.8M | ||
| Q2 25 | $134.9M | $121.6M | ||
| Q1 25 | $479.8M | $89.1M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.5B | $35.3M | ||
| Q3 25 | $1.5B | $-8.1M | ||
| Q2 25 | $1.5B | $7.1M | ||
| Q1 25 | $1.5B | $10.7M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $5.2B | $154.7M | ||
| Q3 25 | $4.7B | $133.7M | ||
| Q2 25 | $4.5B | $133.8M | ||
| Q1 25 | $4.5B | $103.7M | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.8B | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | $5.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.0M | $-2.0M |
| Free Cash FlowOCF − Capex | $78.7M | $-2.1M |
| FCF MarginFCF / Revenue | 352.4% | -15.3% |
| Capex IntensityCapex / Revenue | 37.4% | 0.7% |
| Cash ConversionOCF / Net Profit | 5.49× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $118.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.0M | $-2.0M | ||
| Q3 25 | $26.3M | $-17.5M | ||
| Q2 25 | $44.0M | $-14.5M | ||
| Q1 25 | $-28.7M | $29.0M | ||
| Q4 24 | $133.9M | — | ||
| Q3 24 | $169.0M | — | ||
| Q2 24 | $45.4M | — | ||
| Q1 24 | $-20.4M | — |
| Q4 25 | $78.7M | $-2.1M | ||
| Q3 25 | $25.9M | — | ||
| Q2 25 | $43.4M | $-14.9M | ||
| Q1 25 | $-29.6M | $29.0M | ||
| Q4 24 | $127.4M | — | ||
| Q3 24 | $166.0M | — | ||
| Q2 24 | $44.9M | — | ||
| Q1 24 | $-21.7M | — |
| Q4 25 | 352.4% | -15.3% | ||
| Q3 25 | 93.1% | — | ||
| Q2 25 | 201.6% | -184.0% | ||
| Q1 25 | -145.6% | 988.3% | ||
| Q4 24 | 468.2% | — | ||
| Q3 24 | 432.1% | — | ||
| Q2 24 | 131.0% | — | ||
| Q1 24 | -58.6% | — |
| Q4 25 | 37.4% | 0.7% | ||
| Q3 25 | 1.7% | 0.0% | ||
| Q2 25 | 2.9% | 5.0% | ||
| Q1 25 | 4.3% | 0.8% | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 5.49× | -0.19× | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 2.57× | — | ||
| Q1 25 | -2.49× | — | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | 6.13× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | -1.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
